RAPP
Rapport Therapeutics Inc

381
Mkt Cap
$1.41B
Volume
370,769.00
52W High
$42.27
52W Low
$7.73
PE Ratio
-11.01
RAPP Fundamentals
Price
$30.24
Prev Close
$29.65
Open
$29.00
50D MA
$28.32
Beta
1.43
Avg. Volume
286,131.96
EPS (Annual)
-$2.14
P/B
2.76
Rev/Employee
$0.00
$345.02
Loading...
Loading...
News
all
press releases
Rapport Therapeutics (RAPP) to Release Quarterly Earnings on Tuesday
Rapport Therapeutics (NASDAQ:RAPP) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 10. (View Earnings Report at...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Rapport Therapeutics (NASDAQ:RAPP) Raised to Hold at Wall Street Zen
Wall Street Zen raised shares of Rapport Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·7d ago
News Placeholder
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells 8,500 Shares of Stock
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider David Bredt sold 8,500 shares of the firm's stock in a transaction on Tuesday, February 17th. The shares were sold at an average...
MarketBeat·15d ago
News Placeholder
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) CEO Sells 5,833 Shares of Stock
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) CEO Abraham Ceesay sold 5,833 shares of the company's stock in a transaction dated Wednesday, February 18th. The shares were sold at an...
MarketBeat·15d ago
News Placeholder
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $246,670.00 in Stock
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider David Bredt sold 8,500 shares of Rapport Therapeutics stock in a transaction on Tuesday, February 17th. The stock was sold at an...
MarketBeat·15d ago
News Placeholder
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the firm...
MarketBeat·22d ago
News Placeholder
Rapport Therapeutics (NASDAQ:RAPP) Stock Rating Lowered by Wall Street Zen
Wall Street Zen lowered shares of Rapport Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·28d ago
News Placeholder
Rapport Therapeutics (NASDAQ:RAPP) Upgraded to Hold at Wall Street Zen
Wall Street Zen raised Rapport Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday...
MarketBeat·1mo ago
News Placeholder
Abraham Ceesay Sells 5,833 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) CEO Abraham Ceesay sold 5,833 shares of Rapport Therapeutics stock in a transaction that occurred on Tuesday, January 20th. The stock was...
MarketBeat·1mo ago
News Placeholder
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Short Interest Up 20.7% in December
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totaling 2,692,137...
MarketBeat·2mo ago
<
1
2
...
>

Latest RAPP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.